Completed PHASE3 INTERVENTIONAL NCT00093158

Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)

The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation

Sponsor: The Medicines Company

Conditions Acute Disease Myocardial Infarction Unstable Angina

Interventions Angiomax (bivalirudin) anticoagulant

Updated 5 times since 2017 Last updated: Aug 20, 2007 Started: Aug 31, 2003 Completion: Jan 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00093158, this PHASE3 trial focuses on Acute Disease and Myocardial Infarction and remains completed. Sponsored by The Medicines Company, it has been updated 5 times since 2003, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Medicines Company

Data source: The Medicines Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States